生命科学资讯

5 CDER directors in one year? Turnover threatens ‘institutional memory’ at US health agencies.

After years of debate, the Biosecure Act could be headed for Trump’s desk

Amylyx pins its next hopes on a niche drug in the obesity space

Pharma’s top deals in 2025

Will 2026 be pharma’s M&A breakout year?

Another genetic testing company? Why a different approach could boost drug predictions and R&D.

How Lilly uses Big Pharma heft to lift up-and-coming biotechs

Standout drug approvals in 2025

Unifying life sciences insights to accelerate enterprise value

2026: The year AI’s role in pharma shifts from analysis to action

FDA conflicts of interest extend beyond adcomm experts

BeOne brought Brukinsa to the blood cancer mountaintop. Can it hit those heights again?

Hemophilia gene therapies are struggling on the market, even as innovation soars

4 major changes at the FDA this year

Novo, J&J Alzheimer’s clinical flops teach bruised field valuable lessons

A drugmaker charts a path through pharma’s ethical minefields

Redefining CAR-T speed and strength with DAR-T™: A conversation with Nicholas Kirian

Along with NIH cuts come risks to patient safety and scientific data

4 takeaways from pharma’s manufacturing boom

Eli Lilly becomes first drugmaker to hit $1 trillion in market value